Hyper Corporation Inc. (KOSDAQ:065650)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,100.00
+70.00 (3.45%)
At close: Apr 28, 2026
13.64%
Market Cap 41.87B
Revenue (ttm) 76.19B
Net Income (ttm) -315.64M
Shares Out 21.86M
EPS (ttm) -57.00
PE Ratio 105.59
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,028
Average Volume 146,544
Open 2,035.00
Previous Close 2,030.00
Day's Range 2,035.00 - 2,190.00
52-Week Range 1,600.00 - 7,250.00
Beta 1.52
RSI 45.28
Earnings Date May 15, 2026

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 1997
Employees 46
Stock Exchange KOSDAQ
Ticker Symbol 065650
Full Company Profile

Financial Performance

In 2025, Hyper Corporation's revenue was 76.19 billion, an increase of 32.04% compared to the previous year's 57.70 billion. Losses were -315.64 million, -99.61% less than in 2024.

Financial Statements

News

There is no news available yet.